Further, in T2D hypertensive patients with coronary artery disease, 12 months of receiving GE containing Resv (8 mg) did not alter the blood pressure, glucose, or inflammatory markers except for a significant decline in alkaline phosphatase and Interleukin-6 (IL-6) [112]. The gene discussed is IL6; the disease is coronary artery disorder.